Advertisement

Topics

Boehringer Ingelheim achieves good growth in the first half of 2017

06:00 EDT 9 Aug 2017 | World Pharma News

Boehringer IngelheimBoehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24 per cent on the same period in the previous year to 9.2 billion euros after adjustment for currency effects (+27 per cent in euro terms).(1) In the first half of the year, Boehringer Ingelheim's figures for the first time included the net sales of Sanofi’s animal health business, Merial, which was acquired at the start of the year.

Original Article: Boehringer Ingelheim achieves good growth in the first half of 2017

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim achieves good growth in the first half of 2017"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...